We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Ico4.2
Icosapent Ethyl (Vascepa) Research
Mostly mechanism / observationalLimited safety
7 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Icosapent Ethyl (Vascepa) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2011–2025 with a typical study size of 8,179 participants.
Based on 7 studies · 1 meta-analysis · 5 RCTs · 29,436 total participants
Confidence
High
By outcome
Triglycerides & lipids
Mostly mechanism / observational6 studies
Cardiovascular events
Mostly mechanism / observational5 studies
Metabolic & cardiometabolic risk
Mostly mechanism / observational3 studies
Safety profile
Mostly mechanism / observational3 studies
Steady research
2 studies in the last 5 years · Latest meta-analysis: 2022
201120182025
1RCTn=8,179 · very large study2019
Among patients with elevated triglyceride levels despite statin therapy, the risk of ischemic events was significantly lower among those who received 2 g of icosapent ethyl twice daily.
Bhatt, Steg, Miller, Brinton, Jacobson, Ketchum · The New England journal of medicine (2019)
REDUCE-IT: 8,179 statin-treated patients with elevated triglycerides and high cardiovascular risk
~25% relative reduction in the primary composite of cardiovascular death, MI, stroke, revascularization, and unstable angina
Among statin-treated patients at high cardiovascular risk, the addition of a high-dose omega-3 carboxylic acid did not significantly reduce major adverse cardiovascular events versus corn oil.
Omega-3 supplements were not statistically significantly associated with reduced all-cause mortality, cardiac death, MI, or stroke, with the exception of reduced cardiac mortality only for the equivalent dose of 2 capsules/day (RR 0.55) ... higher doses and particularly for the unique type of omega-3 icosapent ethyl ester should be further addressed.
Random-effects meta-analysis of 19 double-blind omega-3 RCTs (97,709 participants) on major adverse cardiovascular events, with EPA-dose meta-regression and trial-sequential analysis
Omega-3 was NOT significantly associated with all-cause mortality, cardiac death, MI or stroke overall; the only positive signal was reduced cardiac mortality at the equivalent of 2 capsules/day (RR 0.55)
Meta-regression on EPA dose was not statistically significant; the authors conclude that higher doses, and icosapent ethyl specifically, should be further addressed rather than assumed beneficial
The REDUCE-IT randomized trial demonstrated a cardiovascular benefit of icosapent ethyl but also raised potential safety signals for atrial fibrillation and serious bleeding.
Patil, Gregory, Savona, Jarmukli, Leonard · Clinical drug investigation (2025)
Retrospective active-comparator cohort in US Veterans Affairs data (icosapent ethyl vs mixed omega-3)
Examined real-world rates of new-onset atrial fibrillation and major bleeding
Provides real-world context for the AF and bleeding safety signals from REDUCE-IT